Jeanne Thoma Sells 1,000 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Jeanne Thoma sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $71.53, for a total value of $71,530.00. Following the transaction, the director directly owned 26,762 shares in the company, valued at $1,914,285.86. The trade was a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP traded up $0.21 during mid-day trading on Monday, reaching $70.40. 357,649 shares of the company were exchanged, compared to its average volume of 331,768. The company’s 50-day simple moving average is $76.97 and its 200-day simple moving average is $78.17. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.62 billion, a P/E ratio of 15.17 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $99.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. grew its stake in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in ANI Pharmaceuticals in the second quarter valued at $76,000. State of Wyoming bought a new position in ANI Pharmaceuticals during the 2nd quarter worth $86,000. Finally, Kingdom Financial Group LLC. acquired a new position in ANI Pharmaceuticals during the 4th quarter worth about $141,000. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the topic of several recent research reports. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim reduced their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Canaccord Genuity Group lowered their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock. Finally, Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $105.57.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.